Intrapallidal administration of 6-hydroxydopamine mimics in large part the electrophysiological and behavioral consequences of major dopamine depletion in the rat.
Identifieur interne : 000713 ( PubMed/Curation ); précédent : 000712; suivant : 000714Intrapallidal administration of 6-hydroxydopamine mimics in large part the electrophysiological and behavioral consequences of major dopamine depletion in the rat.
Auteurs : P M Abedi [France] ; C. Delaville ; P. De Deurwaerdère ; W. Benjelloun ; A. BenazzouzSource :
- Neuroscience [ 1873-7544 ] ; 2013.
English descriptors
- KwdEn :
- Adrenergic Agents (administration & dosage), Animals, Chromatography, High Pressure Liquid, Dopamine (metabolism), Globus Pallidus (drug effects), Globus Pallidus (metabolism), Injections, Intraventricular, Male, Motor Activity (drug effects), Neurons (metabolism), Oxidopamine (administration & dosage), Parkinson Disease (metabolism), Patch-Clamp Techniques, Rats, Rats, Sprague-Dawley.
- MESH :
- chemical , administration & dosage : Adrenergic Agents, Oxidopamine.
- chemical , metabolism : Dopamine.
- drug effects : Globus Pallidus, Motor Activity.
- metabolism : Globus Pallidus, Neurons, Parkinson Disease.
- Animals, Chromatography, High Pressure Liquid, Injections, Intraventricular, Male, Patch-Clamp Techniques, Rats, Rats, Sprague-Dawley.
Abstract
In addition to GABA and glutamate innervations, the globus pallidus (GP) receives dopamine afferents from the pars compacta of the substantia nigra (SNc), and in turn, sends inhibitory GABAergic efferents to the subthalamic nucleus (STN) and the pars reticulata of the substantia nigra (SNr). Nevertheless, the role of dopamine in the modulation of these pallido-subthalamic and pallido-nigral projections is not known. The present study aimed to investigate the effects of intrapallidal injection of 6-hydroxydopamine (6-OHDA) on the electrical activity of STN and SNr neurons using in vivo extracellular single unit recordings in the rat and on motor behaviors, using the "open field" actimeter and the stepping test. We show that intrapallidal injection of 6-OHDA significantly decreased locomotor activity and contralateral paw use. Electrophysiological recordings show that 6-OHDA injection into GP significantly increased the number of bursty cells in the STN without changing the firing rate, while in the SNr neuronal firing rate decreased and the proportion of irregular cells increased. Our data provide evidence that intrapallidal injection of 6-OHDA resulted in motor deficits paralleled by changes in the firing activity of STN and SNr neurons, which mimic in large part those obtained after major dopamine depletion in the classical rat model of Parkinson's disease. They support the assumption that in addition to its action in the striatum, dopamine mediates its regulatory function at various levels of the basal ganglia circuitry, including the GP.
DOI: 10.1016/j.neuroscience.2013.01.043
PubMed: 23376117
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000745
Links to Exploration step
pubmed:23376117Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intrapallidal administration of 6-hydroxydopamine mimics in large part the electrophysiological and behavioral consequences of major dopamine depletion in the rat.</title>
<author><name sortKey="Abedi, P M" sort="Abedi, P M" uniqKey="Abedi P" first="P M" last="Abedi">P M Abedi</name>
<affiliation wicri:level="1"><nlm:affiliation>Univ. Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France. abdelhamid.benazzouz@u-bordeaux2.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Delaville, C" sort="Delaville, C" uniqKey="Delaville C" first="C" last="Delaville">C. Delaville</name>
</author>
<author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name>
</author>
<author><name sortKey="Benjelloun, W" sort="Benjelloun, W" uniqKey="Benjelloun W" first="W" last="Benjelloun">W. Benjelloun</name>
</author>
<author><name sortKey="Benazzouz, A" sort="Benazzouz, A" uniqKey="Benazzouz A" first="A" last="Benazzouz">A. Benazzouz</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23376117</idno>
<idno type="pmid">23376117</idno>
<idno type="doi">10.1016/j.neuroscience.2013.01.043</idno>
<idno type="wicri:Area/PubMed/Corpus">000745</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000745</idno>
<idno type="wicri:Area/PubMed/Curation">000713</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000713</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Intrapallidal administration of 6-hydroxydopamine mimics in large part the electrophysiological and behavioral consequences of major dopamine depletion in the rat.</title>
<author><name sortKey="Abedi, P M" sort="Abedi, P M" uniqKey="Abedi P" first="P M" last="Abedi">P M Abedi</name>
<affiliation wicri:level="1"><nlm:affiliation>Univ. Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France. abdelhamid.benazzouz@u-bordeaux2.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Delaville, C" sort="Delaville, C" uniqKey="Delaville C" first="C" last="Delaville">C. Delaville</name>
</author>
<author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name>
</author>
<author><name sortKey="Benjelloun, W" sort="Benjelloun, W" uniqKey="Benjelloun W" first="W" last="Benjelloun">W. Benjelloun</name>
</author>
<author><name sortKey="Benazzouz, A" sort="Benazzouz, A" uniqKey="Benazzouz A" first="A" last="Benazzouz">A. Benazzouz</name>
</author>
</analytic>
<series><title level="j">Neuroscience</title>
<idno type="eISSN">1873-7544</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Agents (administration & dosage)</term>
<term>Animals</term>
<term>Chromatography, High Pressure Liquid</term>
<term>Dopamine (metabolism)</term>
<term>Globus Pallidus (drug effects)</term>
<term>Globus Pallidus (metabolism)</term>
<term>Injections, Intraventricular</term>
<term>Male</term>
<term>Motor Activity (drug effects)</term>
<term>Neurons (metabolism)</term>
<term>Oxidopamine (administration & dosage)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Patch-Clamp Techniques</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adrenergic Agents</term>
<term>Oxidopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Globus Pallidus</term>
<term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Globus Pallidus</term>
<term>Neurons</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chromatography, High Pressure Liquid</term>
<term>Injections, Intraventricular</term>
<term>Male</term>
<term>Patch-Clamp Techniques</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In addition to GABA and glutamate innervations, the globus pallidus (GP) receives dopamine afferents from the pars compacta of the substantia nigra (SNc), and in turn, sends inhibitory GABAergic efferents to the subthalamic nucleus (STN) and the pars reticulata of the substantia nigra (SNr). Nevertheless, the role of dopamine in the modulation of these pallido-subthalamic and pallido-nigral projections is not known. The present study aimed to investigate the effects of intrapallidal injection of 6-hydroxydopamine (6-OHDA) on the electrical activity of STN and SNr neurons using in vivo extracellular single unit recordings in the rat and on motor behaviors, using the "open field" actimeter and the stepping test. We show that intrapallidal injection of 6-OHDA significantly decreased locomotor activity and contralateral paw use. Electrophysiological recordings show that 6-OHDA injection into GP significantly increased the number of bursty cells in the STN without changing the firing rate, while in the SNr neuronal firing rate decreased and the proportion of irregular cells increased. Our data provide evidence that intrapallidal injection of 6-OHDA resulted in motor deficits paralleled by changes in the firing activity of STN and SNr neurons, which mimic in large part those obtained after major dopamine depletion in the classical rat model of Parkinson's disease. They support the assumption that in addition to its action in the striatum, dopamine mediates its regulatory function at various levels of the basal ganglia circuitry, including the GP.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23376117</PMID>
<DateCreated><Year>2013</Year>
<Month>03</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted><Year>2013</Year>
<Month>08</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7544</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>236</Volume>
<PubDate><Year>2013</Year>
<Month>Apr</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>Neuroscience</Title>
<ISOAbbreviation>Neuroscience</ISOAbbreviation>
</Journal>
<ArticleTitle>Intrapallidal administration of 6-hydroxydopamine mimics in large part the electrophysiological and behavioral consequences of major dopamine depletion in the rat.</ArticleTitle>
<Pagination><MedlinePgn>289-97</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuroscience.2013.01.043</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0306-4522(13)00080-8</ELocationID>
<Abstract><AbstractText>In addition to GABA and glutamate innervations, the globus pallidus (GP) receives dopamine afferents from the pars compacta of the substantia nigra (SNc), and in turn, sends inhibitory GABAergic efferents to the subthalamic nucleus (STN) and the pars reticulata of the substantia nigra (SNr). Nevertheless, the role of dopamine in the modulation of these pallido-subthalamic and pallido-nigral projections is not known. The present study aimed to investigate the effects of intrapallidal injection of 6-hydroxydopamine (6-OHDA) on the electrical activity of STN and SNr neurons using in vivo extracellular single unit recordings in the rat and on motor behaviors, using the "open field" actimeter and the stepping test. We show that intrapallidal injection of 6-OHDA significantly decreased locomotor activity and contralateral paw use. Electrophysiological recordings show that 6-OHDA injection into GP significantly increased the number of bursty cells in the STN without changing the firing rate, while in the SNr neuronal firing rate decreased and the proportion of irregular cells increased. Our data provide evidence that intrapallidal injection of 6-OHDA resulted in motor deficits paralleled by changes in the firing activity of STN and SNr neurons, which mimic in large part those obtained after major dopamine depletion in the classical rat model of Parkinson's disease. They support the assumption that in addition to its action in the striatum, dopamine mediates its regulatory function at various levels of the basal ganglia circuitry, including the GP.</AbstractText>
<CopyrightInformation>Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abedi</LastName>
<ForeName>P M</ForeName>
<Initials>PM</Initials>
<AffiliationInfo><Affiliation>Univ. Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France. abdelhamid.benazzouz@u-bordeaux2.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Delaville</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>De Deurwaerdère</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Benjelloun</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Benazzouz</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>01</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Neuroscience</MedlineTA>
<NlmUniqueID>7605074</NlmUniqueID>
<ISSNLinking>0306-4522</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018663">Adrenergic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber>
<NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D018663" MajorTopicYN="N">Adrenergic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005917" MajorTopicYN="N">Globus Pallidus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>12</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2013</Year>
<Month>01</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>01</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>2</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>2</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>8</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23376117</ArticleId>
<ArticleId IdType="pii">S0306-4522(13)00080-8</ArticleId>
<ArticleId IdType="doi">10.1016/j.neuroscience.2013.01.043</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000713 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000713 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:23376117 |texte= Intrapallidal administration of 6-hydroxydopamine mimics in large part the electrophysiological and behavioral consequences of major dopamine depletion in the rat. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23376117" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |